HRS-5632 / Jiangsu Hengrui Pharma - LARVOL DELTA

Safety, Tolerability, and Lipoprotein(a)-Lowering Effect of HRS-5632, an Extended Long-Acting Small Interfering RNA Targeting Lipoprotein(a): A Randomized, Double-Blind, First-in-Human Study (AHA 2026) - "Abstract is embargoed at this time."

Clinical • First-in-human • P1 data

HRS-5632-101: A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Dyslipidemia • Metabolic Disorders

A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (clinicaltrials.gov) - P2 | N=203 | Active, not recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular

A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular

A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P2 trial • Cardiovascular

HRS-5632-101: A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Dyslipidemia • Metabolic Disorders

HRS-5632-101: A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P1 trial • Dyslipidemia • Metabolic Disorders